Peapod Lane Capital LLC Makes New $1.40 Million Investment in Aadi Bioscience, Inc. (NASDAQ:AADI)

Peapod Lane Capital LLC acquired a new stake in Aadi Bioscience, Inc. (NASDAQ:AADI - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 442,942 shares of the company's stock, valued at approximately $1,397,000. Peapod Lane Capital LLC owned about 1.80% of Aadi Bioscience at the end of the most recent reporting period.

Separately, XTX Topco Ltd bought a new position in Aadi Bioscience during the 3rd quarter valued at about $32,000. Hedge funds and other institutional investors own 52.08% of the company's stock.

Aadi Bioscience Trading Down 0.8 %

Shares of AADI stock traded down $0.02 on Monday, reaching $2.59. 108,349 shares of the company's stock were exchanged, compared to its average volume of 182,094. The company's fifty day simple moving average is $2.92 and its 200 day simple moving average is $2.27. The stock has a market capitalization of $63.97 million, a PE ratio of -1.14 and a beta of 0.64. Aadi Bioscience, Inc. has a 52 week low of $1.21 and a 52 week high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.